Younger women (aged Յ50 years) who underwent breast conservation therapy may benefit from breast magnetic resonance imaging (MRI) screening as an adjunct to mammography.
W omen who are treated with breast conservation surgery and radiotherapy (BCT) remain at an increased risk for second breast cancers, which can be either a local recurrence or a new primary in the conserved and contralateral breast at 5-year (approximately 10%) and 10-year (approximately 20%) follow-up visits.
1-3 Because early detection of second breast cancers at the asymptomatic phase in breast cancer survivors can improve their relative survival by27%to47%, 4 the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend annual mammography screening or surveillance for women who received BCT. [5] [6] [7] However, although mammography screening detects early-stage second breast cancers, lower sensitivity and higher interval cancer rates were observed in women with a personal history of breast cancer compared with women without, especially in women 50 years or younger and those with extremely dense breasts.
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The American Cancer Society guideline suggests that there is insufficient evidence to recommend or advise against annual magnetic resonance imaging (MRI) screenings for women with a personal history of breast cancer, while MRI screening is recommended as an adjunct to mammography for women with genetic mutations or women with more than a 20% to 25% lifetime risk of breast cancer. 9 Women with a personal history of breast cancer, however, have a heterogeneous risk for developing a second breast cancer. 10 According to a model of cancer risk, women with early-stage, hormone receptor-positive breast cancer who were not BRCA mutation carriers fit a 20% lifetime cancer-risk threshold for developing a second breast cancer if they were 50 years or younger and had undergone BCT but not a total mastectomy. 11 As MRI or ultrasonography screenings to detect second breast cancers in women after BCT have been increasingly used [12] [13] [14] [15] despite limited evidence regarding their comparative effectiveness, it has been reported that 45% to 54% of women who were screened for breast cancer using MRI or ultrasonography had a personal history of breast cancer. 14,15 Retrospective studies have shown similar cancer detection rates but significantly lower false-positive screening, defined as an unnecessary recall, biopsy, or short-term follow-up of MRI or ultrasonography screening in women with a personal history of breast cancer compared with those without a personal history of breast cancer or those with a genetic risk for or a family history of breast cancer. 15, 16 To our knowledge, there has been no prospective study to compare, among the same participants, the performance of a combination of imaging techniques for breast cancer screening: mammography and MRI or ultrasonography vs mammography alone for women after BCT. Thus, the purpose of our study was to compare outcomes of a combined mammography and MRI or ultrasonography screening in women who had received BCT for breast cancer before age 50 years.
Methods

Study Participants and Study Conduct
For this prospective, nonrandomized, multicenter, observational cohort study (clinicaltrials.gov Identifier: NCT01257152), we recruited asymptomatic women who were 50 years or younger at the initial diagnosis of breast cancer, who had undergone BCT, and who came in for a mammogram at 6 different academic centers (Seoul National University Hospital, The inclusion criteria were as follows: women 20 years or older and 50 years or younger at the initial diagnosis of ductal carcinoma in situ or invasive breast cancer; women whose final margins were negative, defined as no ink on tumor and who had finished radiotherapy at least 6 months before the study; women with no history of a breast biopsy within 6 months prior to the study; women who had not had contralateral mastectomies; women who had no known metastatic disease; women who were not pregnant or lactating; women who had no present signs or symptoms of breast cancer; women with no contraindications to MRI examinations; and women with no prior breast MRI, breast ultrasonography, or mammography screenings within 6 months before the study. Radiotherapy and systemic treatment protocol was standardized across the academic centers according to the National Comprehensive Cancer Network guidelines.
7 Annual mammography, breast ultrasonography, and breast MRI were performed for both conserved and contralateral breasts during the 3-year study period-from December 1, 2010, to January 31, 2016-with a maximum interval of 2 months between each imaging modality. Clinical breast examinations were performed every 6 months. 5, 6 Two-view mammograms, including mediolateral oblique and craniocaudal view, were performed using fullfield digital mammography units. Whole-breast screening ultrasonography was performed by radiologists (N.C., B. Guidance modality was determined at the discretion of the radiologists who interpreted images. The MRIguided, vacuum-assisted biopsy was performed for lesions identified on MRI alone. Determination of cancer was made on the basis of the biopsy or imaging follow-up results within 365 days after the imaging examinations. Cancer detection rate (CDR), sensitivity, specificity, recall rate, positive predictive value for recall (PPV 1 ), short-term follow-up rate, biopsy rate, PPV for biopsy (PPV 3 ), and diagnostic accuracy assessed by area under the (receiver operating characteristic) curve (AUC) were calculated for each imaging modality and its respective combinations. 20 The CDR was defined as the number of detected cancers per 1000 examinations. A negative examination result was defined as a BI-RADS category of 1 or 2, and a positive examination result was defined as a BI-RADS category of 3, 4A, 4B, 4C, or 5. An interval cancer was defined as a breast cancer diagnosed after the last negative examination result because of clinical symptoms but before the next scheduled examination.
Statistical Analysis
We compared screening outcomes between each image modality and its combinations using generalized estimating equations, where a participant was defined as a cluster, or McNemar test. The independence working correlation structure was used for PPV or negative predictive value, and the exchangable correlation structure was used for the other outcomes in the generalized estimating equation. The AUCs were estimated and compared using the method accounting for the correlations. 21 The 95% CIs of CDR, specificity, recall rate, PPV 1 , short-term follow-up, and biopsy rate were estimated considering a participant as a cluster. 22 Because the number of detected or diagnosed cancers was small, exact CI for sensitivity was estimated by the Wilson score method. The adjusted P values for multiple testing were calculated using the Sidak method for each screening outcome. Clinicopathologic features and treatment data of the initial breast cancers were also obtained and compared between the women with and without second breast cancers using the Fisher exact test. The features showing P < .20 were included for multivariable logistic regression analysis to identify independent factors associated with second breast cancers. The stepwise variable selection method was applied. Statistical analyses were performed using SAS software, version 9.2 (SAS Institute Inc). A 2-sided P < .05 was considered to indicate a significant difference, and CIs are shown at the 95% confidence level.
Results
Participant Characteristics
From December 1, 2010, through January 31, 2016, a total of 754 eligible women participated in the study. Of these women, 2 (0.3%) did not undergo mammography but underwent ultrasonography and MRI in the first round, completed the second and third rounds, and were included for the second-year and third-year analyses but excluded from the first-year analysis ( Figure) . Systemic metastasis was found in 7 women (0.9%), and they were excluded from the study. No MRI examination results were excluded because of poor image quality. Thus, a total of 754 women with reference standards completed 2065 screenings: 752 screenings in the first year, 689 in the second year, and 624 in the third year ( Table 1) . Six hundred ninetythree participants (91.9%) underwent a preoperative MRI. Sixty-one women (8.1%) underwent genetic testing and 17 (2.3%) were found to be BRCA mutation carriers, and 2 of the 17 had second breast cancers. Characteristics of the study cohort, including clinicopathologic features and treatment data of initial breast cancers, can be found in eAppendix in the Supplement.
Cancer Detection, Interval Cancer Rate, and Tumor Characteristics A total of 17 breast cancers were identified in 17 women (2.3%): 12 identified in the first year, 3 in the second year, and 2 in the third year. The mean time from the initial surgery to the detection of a second breast cancer was 17.8 (range, 6-41) months (range, 6-41 months). All cancers were detected by 1 of 3 imaging modalities. No cancer was detected on clinical breast examinations. No cancer was found during the intervals between screenings and at the 12-month follow-up after the thirdyear interpretation.
Of the 17 women with detected cancers, 10 (58.8%) were diagnosed with cancer in the ipsilateral breast and 7 (41.2%) were diagnosed with cancer in the contralateral breast, and 13 (76.5%) were in stage 0 or stage 1. Only 1 cancer (5.9%) had nodal micrometastasis, and 10 (58.8%) were invasive ductal carcinomas with a median (interquartile range) size of 10.5 (14.5) mm. Two cancers (11.8%) were detected by mammog- 
Incremental Cancer Detection Yield
The overall CDR was 8.2 per 1000 examinations (17 of 2065) ( Table 2 ). The CDR of mammography with MRI was higher than that of mammography alone (8.2 vs 4.4 per 1000; P = .003). The CDR of mammography with ultrasonography was higher than that of mammography alone (6.8 vs 4.4 per 1000; P = .03). When MRI was added to mammography, 3.8 more cancers per 1000 women (95% CI, 2.8-4.9; P = .003) were detected. When ultrasonography was added to mammography, 2.4 more cancers per 1000 women (95% CI, 1.7-3.1; P = .03) were detected.
Regarding the yield for invasive carcinoma, when MRI was added to mammography, 2.4 more cancers per 1000 women were detected (95% CI, 1.5-3.3; P = .03). When ultrasonography was added to mammography, 1.5 more cancers per 1000 women were detected (95% CI, 0.9-2.0; P = .12) (eTable 3 in the Supplement).
Sensitivity, Specificity, and AUC
The sensitivity of mammography with MRI screening (100% [17 of 17]; 95% CI, 81.6%-100%) was higher than that of mammography alone (52.9% [9 of 17]; 95% CI, 31.0%-73.8%; P = .01) ( Table 2) .
The AUC increased from 0.79 (95% CI, 0.65-0.93) to 0.99 (95% CI, 0.94-1.00) (P = .01) when MRI was added to mammography; however, the AUC was not significantly differently increased from 0.79 (95% CI, 0.65-0.93) to 0.92 (95% CI, 0.84-1.00) (P = .18) when ultrasonography was added to mammography (Table 2) .
Recall, Biopsy, and Short-term Follow-up Rates
After the addition of MRI to mammography, there was an increase in the recall rate from 4.4% (91 of 2065; 95% CI, 3.3%-5.5%) to 13.8% (284 of 2065; 95% CI, 12.0%-15.5%; P < .001), in the biopsy rate from 0.5% (11 of 2065; 95% CI, 0.2%-0.8%) to 2.7% (56 of 2065; 95% CI, 2.0%-3.4%; P < .001), and in the short-term follow-up rate from 3.6% (75 of 2065; 95% CI, 2.6%-4.7%) to 10.2% (210 of 2065; 95% CI, 8.6%-11.8%; P < .001) ( Table 2) . After the addition of ultrasonography to mammography, the recall rate, biopsy rate, and short-term follow-up rate (each of which has P < .001) also increased (Table 2) .
PPV for Recall and Biopsy
The PPV 1 for the recall was not different after the addition of MRI (9.9% [9 of 91]; 95% CI, 3.6%-16.2% vs 6.0% [17 of 284]; 95% CI, 3.2%-8.8%; P = .09), although the PPV 1 was significantly decreased when ultrasonography was added to mammography alone (9.9% 
Characteristics of Women With Second Breast Cancers
Characteristics of women with second breast cancers and women without second breast cancers are summarized in eTable 4 in the Supplement.
Discussion
In this study, the results showed that for women who had received BCT for breast cancer at 50 years or younger, the addition of MRI to a mammography increased screening sensitivity (100% vs 52.9%; P = .01) and detected 3.8 (95% CI, 2.8-4.9; P = .003) more cancers per 1000 women compared with mammography Regarding the overall CDR, our rate of 8.2 per 1000 examinations (17 of 2065) is lower than the CDR range of 16 to 30 per 1000 for women who have familial breast cancer or are BRCA mutation carriers. [23] [24] [25] [26] [27] The relatively lower CDR in this study might be because 91.9% (693 of 754) of our participants had undergone preoperative MRI that had been reported to be associated with a reduced second breast cancer incidence in contralateral breasts. 30 In addition, women at the highest risk of recurrence (whose final margins were positive or who did not receive radiotherapy) were excluded from the study. In previous retrospective studies carried out in single center for women with a personal history of breast cancers, a highly selected population with negative mammography or nonblinded interpretation of mammography results and MRI might have overestimated CDR for MRI screenings.
One of the major drawbacks of MRI screening is its high false-positive rate and, as a result, the associated costs and morbidity. Compared with mammography alone, the addition of MRI increased the recall rate (from 4.4% to 13.8%; P < .001), biopsy rate (from 0.5% to 2.7%; P < .001), and short-term follow-up rate (from 3.6% to 10.2%; P < .001), which led to decreased specificity (from 96% to 87%; P < .001). However, 47.1% (8 of 17) of cancers might have been missed with mammography alone. Considering the harms caused by false-negative findings, the false-positive findings caused by MRI screening examinations might be within acceptable ranges if informed women choose them.
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The addition of ultrasonography to mammography screening tended to increase sensitivity of the screening from 52.9% (9 of 17) to 82.4% (14 of 17); however, this difference was not significant at P = . 07. Therefore, when women who received BCT at 50 years or younger, especially those with dense breasts, are unable to undergo MRI screenings, ultrasonography might be considered.
15,32
Limitations
There are several limitations to this study. First, as there was no control group undergoing mammography alone, we were not able to compare the interval cancer rate or advanced stage cancer rate among mammography, ultrasonography, and MRI screening. Second, we could not evaluate the cost-effectiveness and effect of MRI or ultrasonography screening on survival benefit. The use of MRI screening with a 2-year or 3-year interval with abbreviated MRI sequences 33 would be more costeffective. Metastasis-free survival is better in an annual MRI screening group for women with BRCA mutations or familial risk 
Conclusions
This study suggests that the addition of MRI to mammography screening improved the detection of early-stage breast cancers at acceptable specificity in women who had BCT at 50 years or younger. Our study results can be used not only to inform patient and clinician decision making regarding the best methods of screening after BCT but also to develop more personalized screening guidelines and recommendations for women at increased risk for breast cancer. 
